Soft 3D hybrid network for delivery and controlled release of poorly soluble dihydropyrimidinone compound: An insight into the novel system for potential application in leukemia treatment
Само за регистроване кориснике
2022
Аутори
Marković, Maja D.Tadić, Julijana D.
Savić, Sanja I.
Matić, Ivana Z.
Stanojković, Tatjana P.
Mijin, Dušan
Panić, Vesna V.
Чланак у часопису (Објављена верзија)
Метаподаци
Приказ свих података о документуАпстракт
Researchers are faced with everyday demands for safer and more efficient therapy for many diseases, especially serious one such as various types of cancer. Numerous anticancer drugs are poorly-water soluble and therefore their encapsulation and controlled release remain quite challenge. In present study, we deepened our research of hydrophilic carrier based on poly(methacrylic acid) and casein (PMAC) by investigating its potential for encapsulation and controlled release of novel poorly water-soluble dihydropyrimidion-azo-pyridon compound (DHPMP). DHPMP is a dye that has been proven to show cytotoxic activity against chronic myeloid leukemia K562 cells. By encapsulating DHPMP into the carrier and delivering it into the intestines, DHPMP absorption could be the fastest and the number of therapeutic doses and side effects can be reduced. Carriers based on PMAC and DHPMP (PMAC-DHPMP) were synthetized and characterized by FTIR, SEM and single compression tests. The swelling behavior of PMA...C-DHPMP carriers and cumulative DHPMP release were investigated depending on the amount of crosslinker and encapsulated DHPMP in two media which were simulating pH environments in human stomach and intestines. The prolonged and controlled release of DHPMP was achieved. In vitro cytotoxic activity of PMAC-DHPMP carriers against K562 cells and the cell cycle analysis showed great potential of the carriers for application in leukemia treatment.
Кључне речи:
anticancer activity / Biginelli adduct / casein / pH responsive hydrogels / poly(methacrylic acid) / targeted drug deliveryИзвор:
Journal of Biomedical Materials Research - Part A, 2022Издавач:
- John Wiley and Sons Inc
Финансирање / пројекти:
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200287 (Иновациони центар Технолошко-металуршког факултета у Београду доо) (RS-200287)
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200017 (Универзитет у Београду, Институт за нуклеарне науке Винча, Београд-Винча) (RS-200017)
- Министарство науке, технолошког развоја и иновација Републике Србије, институционално финансирање - 200043 (Институт за онкологију и радиологију Србије, Београд) (RS-200043)
DOI: 10.1002/jbm.a.37396
ISSN: 1549-3296
WoS: 00078950770000
Scopus: 2-s2.0-85129106862
Колекције
Институција/група
Inovacioni centarTY - JOUR AU - Marković, Maja D. AU - Tadić, Julijana D. AU - Savić, Sanja I. AU - Matić, Ivana Z. AU - Stanojković, Tatjana P. AU - Mijin, Dušan AU - Panić, Vesna V. PY - 2022 UR - http://TechnoRep.tmf.bg.ac.rs/handle/123456789/5136 AB - Researchers are faced with everyday demands for safer and more efficient therapy for many diseases, especially serious one such as various types of cancer. Numerous anticancer drugs are poorly-water soluble and therefore their encapsulation and controlled release remain quite challenge. In present study, we deepened our research of hydrophilic carrier based on poly(methacrylic acid) and casein (PMAC) by investigating its potential for encapsulation and controlled release of novel poorly water-soluble dihydropyrimidion-azo-pyridon compound (DHPMP). DHPMP is a dye that has been proven to show cytotoxic activity against chronic myeloid leukemia K562 cells. By encapsulating DHPMP into the carrier and delivering it into the intestines, DHPMP absorption could be the fastest and the number of therapeutic doses and side effects can be reduced. Carriers based on PMAC and DHPMP (PMAC-DHPMP) were synthetized and characterized by FTIR, SEM and single compression tests. The swelling behavior of PMAC-DHPMP carriers and cumulative DHPMP release were investigated depending on the amount of crosslinker and encapsulated DHPMP in two media which were simulating pH environments in human stomach and intestines. The prolonged and controlled release of DHPMP was achieved. In vitro cytotoxic activity of PMAC-DHPMP carriers against K562 cells and the cell cycle analysis showed great potential of the carriers for application in leukemia treatment. PB - John Wiley and Sons Inc T2 - Journal of Biomedical Materials Research - Part A T1 - Soft 3D hybrid network for delivery and controlled release of poorly soluble dihydropyrimidinone compound: An insight into the novel system for potential application in leukemia treatment DO - 10.1002/jbm.a.37396 ER -
@article{ author = "Marković, Maja D. and Tadić, Julijana D. and Savić, Sanja I. and Matić, Ivana Z. and Stanojković, Tatjana P. and Mijin, Dušan and Panić, Vesna V.", year = "2022", abstract = "Researchers are faced with everyday demands for safer and more efficient therapy for many diseases, especially serious one such as various types of cancer. Numerous anticancer drugs are poorly-water soluble and therefore their encapsulation and controlled release remain quite challenge. In present study, we deepened our research of hydrophilic carrier based on poly(methacrylic acid) and casein (PMAC) by investigating its potential for encapsulation and controlled release of novel poorly water-soluble dihydropyrimidion-azo-pyridon compound (DHPMP). DHPMP is a dye that has been proven to show cytotoxic activity against chronic myeloid leukemia K562 cells. By encapsulating DHPMP into the carrier and delivering it into the intestines, DHPMP absorption could be the fastest and the number of therapeutic doses and side effects can be reduced. Carriers based on PMAC and DHPMP (PMAC-DHPMP) were synthetized and characterized by FTIR, SEM and single compression tests. The swelling behavior of PMAC-DHPMP carriers and cumulative DHPMP release were investigated depending on the amount of crosslinker and encapsulated DHPMP in two media which were simulating pH environments in human stomach and intestines. The prolonged and controlled release of DHPMP was achieved. In vitro cytotoxic activity of PMAC-DHPMP carriers against K562 cells and the cell cycle analysis showed great potential of the carriers for application in leukemia treatment.", publisher = "John Wiley and Sons Inc", journal = "Journal of Biomedical Materials Research - Part A", title = "Soft 3D hybrid network for delivery and controlled release of poorly soluble dihydropyrimidinone compound: An insight into the novel system for potential application in leukemia treatment", doi = "10.1002/jbm.a.37396" }
Marković, M. D., Tadić, J. D., Savić, S. I., Matić, I. Z., Stanojković, T. P., Mijin, D.,& Panić, V. V.. (2022). Soft 3D hybrid network for delivery and controlled release of poorly soluble dihydropyrimidinone compound: An insight into the novel system for potential application in leukemia treatment. in Journal of Biomedical Materials Research - Part A John Wiley and Sons Inc.. https://doi.org/10.1002/jbm.a.37396
Marković MD, Tadić JD, Savić SI, Matić IZ, Stanojković TP, Mijin D, Panić VV. Soft 3D hybrid network for delivery and controlled release of poorly soluble dihydropyrimidinone compound: An insight into the novel system for potential application in leukemia treatment. in Journal of Biomedical Materials Research - Part A. 2022;. doi:10.1002/jbm.a.37396 .
Marković, Maja D., Tadić, Julijana D., Savić, Sanja I., Matić, Ivana Z., Stanojković, Tatjana P., Mijin, Dušan, Panić, Vesna V., "Soft 3D hybrid network for delivery and controlled release of poorly soluble dihydropyrimidinone compound: An insight into the novel system for potential application in leukemia treatment" in Journal of Biomedical Materials Research - Part A (2022), https://doi.org/10.1002/jbm.a.37396 . .